Notice: ASA extends its thoughts and condolences to those affected by the disaster in Oklahoma. Donations to help aid this relief can be made through the American Red Cross website.

>

WEBINARS

RSS
>

MEETINGS / EVENTS

RSS
>

FDA MEDWATCH ALERTS

RSS

May 20, 2013

All Sterile Drug Products Made and Distributed By NuVision Pharmacy Dallas Facility: Recall - Lack Of Sterility Assurance

Summary:

All Sterile Drug Products Made and Distributed By NuVision Pharmacy Dallas Facility

May 14, 2013

Zolpidem Containing Products: Drug Safety Communication - FDA Requires Lower Recommended Doses

Summary:

Zolpidem Containing Products Drug Safety Communication

May 09, 2013

The Compounding Shop: FDA News Release - Lack of Sterility Assurance of Drug Products

Summary:

The Compounding Shop FDA News Release Lack of Sterility

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Anesthesiology Continuing Education (ACE) Program

SKU: 30702-13CE

... Read more »

Single Copies, Member Price: $360

ASA Submits Comments to OIG on 'Company Model'

Friday, February 25, 2011

The Office of Inspector General (OIG) requested comments on its notice of intent to develop regulations on Special Fraud Alerts. The notice offers ASA and its members an opportunity to recommend that the OIG issue a Special Fraud Alert on the economic model, known as the "company model."  Under the company model, referring physicians, who typically also own the facility where surgical procedures are performed, form a separate anesthesia company in order to share in anesthesia revenue. ASA has written a letter to the OIG on this issue.

Click here to read the letter ASA sent to the OIG.

 

 

« Back to Washington Alerts